Objective
NANOFOL proposes to develop a new diagnostic/therapy approach using folate based nanobiodevices (FBN) able to provide a new type of cost efficient treatment for chronic inflammatory diseases such as Atherosclerosis and Rheumatoid Arthritis with low side effects that will constitute a more advantageous solution than current therapies. NANOFOL will achieve all that by fulfilling the following objectives: •Design , development and production of nanobiodevices (FBN) targeting directly effector cells •Proof of concept in vitro and in vivo of a folate based nanodevice targeting activated macrophages in chronic inflammation not affecting bystander cells •Proof of concept in vitro and in vivo of a nanodevice containing a bispecific antibody (against folate receptor and another macrophage marker) targeting activated macrophages in chronic inflammation not affecting bystander cells •Proof of concept of FBN delivery therapeutic agents (by small interfering ribonucleic acid molecules (siRNA) or lipophylic molecules) targeting inflammatory signaling pathways •In vitro and in vivo testing of cellular toxicity caused by the novel nanobiodevices in cells other than activated macrophages •Design of models that will enable to minimize animal experimentation. •Development of a strategy to assess potential risks in order to ensure nanobiodevice safe delivery. NANOFOL has adopted a specific risk strategy to attain objectives in a step by step approach allowing improving gradually the concept (specificity, stability, side effects efficacy) from the lower to the higher risky solutions ensuring reduced experimental animal testing and high human safety. The NANOFOL project will combine expertise in nanotechnologies, biology, chemistry, materials science, biotechnology, engineering, risk analysis, medical and pharmaceutical sciences.
Fields of science
Programme(s)
Call for proposal
FP7-NMP-2008-LARGE-2
See other projects for this call
Funding Scheme
CP-IP - Large-scale integrating projectCoordinator
4704 553 Braga
Portugal
See on map
Participants (13)
28108 Alcobendas
See on map
Participation ended
8010 Graz
See on map
2595 DA Den Haag
See on map
4200 135 Porto
See on map
75654 Paris
See on map
1090 Wien
See on map
310130 Arad
See on map
72076 Tuebingen
See on map
60550 Verneuil En Halatte
See on map
25242 VESTEC
See on map
92300 Levallois-Perret
See on map
Participation ended
2780-157 Oeiras
See on map
1180 Wien
See on map